Research programme: cancer immunotherapies - Accuro Immunology
Alternative Names: TEIPP-01Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Accuro Immunology
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Sweden
- 03 Nov 2003 Preclinical trials in Cancer in Sweden (unspecified route)